Erythromycin: Difference between revisions
(Text replacement - "==Source==" to "==References==") |
|||
| Line 30: | Line 30: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 2 hours | ||
*Metabolism: | *Metabolism: Liver | ||
*Excretion: | *Excretion: Bile/Renal | ||
*Mechanism of Action: | *Mechanism of Action: Binds to 50S ribosomal unit --> inhibiting protein synthesis | ||
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ||
Revision as of 15:01, 13 October 2017
General
- Type:
- Dosage Forms:
- Common Trade Names:
Adult Dosing
Pre-endoscopy
- 3mg/kg IV over 20-30min, 30-90min prior to endoscopy
- Achieves endoscopy conditions equal to lavage[1]
Pediatric Dosing
Special Populations
- Pregnancy:
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life: 2 hours
- Metabolism: Liver
- Excretion: Bile/Renal
- Mechanism of Action: Binds to 50S ribosomal unit --> inhibiting protein synthesis
Antibiotic Sensitivities[2]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia